Everolimus in colorectal cancer

Bibliography

• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011;20:381-94
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-9
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012;30:78-84
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Lehne G, Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 2004;19:2606-14
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Eisen H, Dorent R, Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 2003;22:1117-25
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Silva HT, Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003;3:606-13
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012;18:2766-77
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Calvo E, Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10
   PubMed Web of Science ®Google Scholar
• Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007;251:105-13
   PubMed Web of Science ®Google Scholar
• Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007;282:23679-86
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang W, Bertram P, Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004;24:893-900
   PubMed Web of Science ®Google Scholar
• Aoki K, Tamai Y, Horiike S, Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet 35:323-30.2003
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-72
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004;5:519-23
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
   PubMed Web of Science ®Google Scholar
• Renner C, Zinzani PL, Gressin R, A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97:1085-91
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
   PubMed Web of Science ®Google Scholar
• Berkel HJ, Turbat-Herrera EA, Shi R, Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 2001;10:663-6
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Chen JJ, Wang S, Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999;18:2507-17
   PubMed Web of Science ®Google Scholar
• Fujishita T, Aoki M, Taketo MM. The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle 2009;8:3684-7
   PubMed Web of Science ®Google Scholar
• Kim DD, Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs 2012
   Web of Science ®Google Scholar
• O'Donnell A, Faivre S, Burris HA III, Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
   PubMed Web of Science ®Google Scholar
• Gold PJ, Iriarte D, Arthur J, Phase II trial of RAD001 in patients with refractory metastatic colorectal cancer. JCO 2008;27(15s): [abstract 513]
   Google Scholar
• Fuchs CS, Tabernero JM, Hwang J, Multicenter phase II study of RAD001 in patients with chemotherapy-refractory metastatic colorectal cancer. JCO 2009;17(15s): [abstract 446]
   Google Scholar
• O'Reilly KE, Rojo F, She QB, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37
   PubMed Web of Science ®Google Scholar
• O'Reilly T, McSheehy PM, Wartmann M, Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011;22:58-78
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010;15:236-45
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22
   PubMed Web of Science ®Google Scholar
• Lane HA, Wood JM, McSheehy PM, mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612-22
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21-6
   PubMed Web of Science ®Google Scholar
• Humar R, Kiefer FN, Berns H, Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349:419-21
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Arnold D, Andre T, Bennouna J, Bevacizumab plus chemotherapy continued beyone first progression in patients with metastatic colorectal cancer previously treated with BEV plus CT. results of a randomized phase III intergroup study (TML study). JCO 2012;30s: [abstract 3503]
   Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J Clin Oncol 2012;30:3499-506
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sobrero AF, Siena S, Phase III CORRECT trial of regorafenib in metastatic colorectal cancer. JCO 2012;30s: [abstract 3502]
   Google Scholar
• Bendell JC, George D, Nixon A, Results of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors. J Clinl Oncol ASCO Ann Meet Proc Part I 2007;25:3548
   Google Scholar
• Bullock KE, Hurwitz H, Uronis HE, Bevacizumab plus everolimus in refractory metastatic colorectal cancer. JCO 2009;27(15s): [abstract 4080]
   Google Scholar
• Altomare I, Bendell JC, Bullock KE, A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 2011;16:1131-7
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Ng K, Zhu AX, Multicenter phase IB/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer. JCO 2012;30(4s): [abstract 560]
   Google Scholar
• Gilcrease GW, Weis JR, Jones K, Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer. JCO 2012;30s: [abstract 600]
   Google Scholar
• Rangwala RA, Bendell J, Kozloff M, Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. JCO 2012;30(4s): [abstract 490]
   Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Tejpar S, Celik I, Schlichting M, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570-7
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7
   PubMed Web of Science ®Google Scholar
• Bianco R, Garofalo S, Rosa R, Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30
   PubMed Web of Science ®Google Scholar
• Shahda S, Yu M, Picus J, Phase I study of everolimus (RAD001) with irinotecan and cetuximab in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102– Final report. JCO 2011;29s: [abstract 3587]
   Google Scholar
• Townsend AR, Pirc L, Hardingham J, A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus in metastatic colorectal cancer with KRAS wild type. JCO 2011;29s: [abstract TPS162]
   Google Scholar
• Davies JM, Raftery LL, Sanoff KH, Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies. JCO 2011;28s: [abstract e13085]
   Google Scholar
• Vlahovic G, Meadows KL, Uronis HE, A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012;70:95-102
   PubMed Web of Science ®Google Scholar
• Strickler JH, Starodub AN, Jia J, Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 2012;70:251-8
   PubMed Web of Science ®Google Scholar
• Hart L, Burris HA, Infante JR, mTOR inhibitor everolimus and IGFR inhibitor OSI-906 for the treatment of patients with refractory metastatic colorectal cancer: A Sarah Cannon Research Institute phase I trial. JCO 2011;29s: [abstract e14054]
   Google Scholar
• Khawaja MR, Younger A, Funke JM, Phase I study of everolimus (RAD001) and AMG479 in patients with advanced solid tumors and colorectal cancer. JCO 2011;29s: [abstract TPS157]
   Google Scholar
• Davies JM, McRee AJ, Sanoff HK, Phase I study of the combination of everolimus (RAD001) with 5FU/LV in patients with refractory solid malignancies. JCO 2011;29(4s): [abstract 512]
   Google Scholar
• van der Vliet JA, Willems MC, de Man BM, Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006;82:1477-83
   PubMed Web of Science ®Google Scholar
• Willems MC, van der Vliet JA, de Man BM, Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010;18:98-104
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-23
   PubMed Web of Science ®Google Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Cicchetti G, Onda H, Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003;112:1223-33
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74
   PubMed Web of Science ®Google Scholar
• Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008;7:3805-9
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Tian XQ, Sun DF, Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009;27:273-85
   PubMed Web of Science ®Google Scholar
• Espina V, Geho D, Mehta AI, Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005;23:36-46
   PubMed Web of Science ®Google Scholar
• Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-20
   PubMed Web of Science ®Google Scholar
• Wang LH, Chan JL, Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int J Cancer 2007;121:157-64
   PubMed Web of Science ®Google Scholar
• Breuleux M, Klopfenstein M, Stephan C, Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009;8:742-53
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601
   PubMed Web of Science ®Google Scholar
• Torres-Arzayus MI, Font de Mora J, Yuan J, High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010;120:2858-66
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Akcakanat A, Chen H, PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012;18:1777-89
   PubMed Web of Science ®Google Scholar